Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 1, 2020
Daily News
October 1, 2020
- Coronavirus Vaccines Must Be Offered to All Humanity: EFPIA Japan Webinar
October 1, 2020
- MHLW’s Review Division Head Stresses Evidence-Based Approval for Coronavirus Vaccines
October 1, 2020
- Metformin Cancer Risk Acceptable at 1 in 550,000 Patients: NIHS Assessment
October 1, 2020
- ASKA, Kyorin to Jointly Develop Benign Prostatic Hyperplasia Drug
October 1, 2020
- MHLW Submits FY2021 Budget, Personnel Requests
October 1, 2020
- Priority Shots for Seasonal Flu Begin for Elderly, Other High-Risk People
October 1, 2020
- Rotavirus Vaccines Now Covered by National Immunization Program
October 1, 2020
- Eisai, Seikagaku Tie Up on Osteoarthritis Med in South Korea
October 1, 2020
- Generic Use Rate at 79.3% in April-June, Just Shy of Govt Target: JGA
October 1, 2020
- Mitsubishi Tanabe Recalls Theodur on Failed Dissolution Test
October 1, 2020
- Shionogi Grabs Global Rights for Univ. of Tokyo Spin-Off’s Novel S. Pneumoniae Nasal Vaccine
October 1, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…